HI-tACS Trial Aims to Improve Executive Control in Gambling Disorder Patients
A randomized controlled trial is assessing the efficacy of high-intensity transcranial alternating current stimulation on executive-control functions in gambling disorder patients.
Phase III
Neurology / Gambling Disorder
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing HI-tACS trial represents a potential breakthrough in the treatment of gambling disorder, which could redefine therapeutic strategies in this area. A successful outcome may not only validate a new treatment modality but also shift competitive dynamics within the neuromodulation market.
Recommended action
Humanexa recommends Monitor.
Analysis
Follow-up assessments and results from the three-month evaluation period will be critical to gauge efficacy.
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.